Systemic Lupus Erythematosus and Mortality in Elderly Patients With Early Breast Cancer.
Journal
Arthritis care & research
ISSN: 2151-4658
Titre abrégé: Arthritis Care Res (Hoboken)
Pays: United States
ID NLM: 101518086
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
29
08
2021
received:
25
01
2021
accepted:
21
09
2021
pubmed:
25
9
2021
medline:
25
2
2023
entrez:
24
9
2021
Statut:
ppublish
Résumé
Patients with cancer and systemic lupus erythematosus (SLE) may have worse outcomes than those without SLE, given their comorbidities. We examined survival in elderly women with breast cancer (BC) and SLE and hypothesized that survival would be decreased compared with women with BC but without SLE. We identified patients with BC and SLE and patients with BC without SLE in the Texas Cancer Registry and Surveillance, Epidemiology, and End Results, linked to Medicare claims. Overall survival (OS) was estimated after matching (age and cancer stage) and in multivariable Cox proportional hazards models adjusting for other cancer characteristics, treatment, and comorbidities. Two additional cohorts of women without cancer with and without SLE were also studied. We identified 494 BC SLE cases and 145,517 BC non-SLE cases, of whom we matched 9,708. Women with SLE were less likely to receive radiation, breast conserving surgery, or endocrine therapy. The 8-year OS estimate for women with early BC (stages 0-II) with and without SLE was 52% (95% confidence interval [95% CI] 45%-59%) and 74% (95% CI 73%-75%), respectively. In the Cox multivariable model, BC and SLE had increased risk of death (hazard ratio [HR] 1.65, 95% CI 1.38-1.98). Women with BC and SLE also had increased risk of death compared with women with SLE but without cancer (HR 1.42, 95% CI 1.05-1.92) after adjusting for SLE severity. Women with SLE and BC received less glucocorticoids, antimalarials, and immunosuppressants after cancer diagnosis than those without cancer. Systemic lupus is a risk factor for increased mortality in women with early BC.
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
559-568Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
© 2021 American College of Rheumatology.
Références
Jorge AM, Lu N, Zhang Y, et al. Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014). Rheumatology (Oxford) 2018;57:337-44.
Yen EY, Shaheen M, Woo JMP, et al. 46-year trends in systemic lupus erythematosus mortality in the United States, 1968 to 2013: a nationwide population-based study. Ann Intern Med 2017;167:777-85.
Ingarvsson RL, Landgren AJ, Bengtsson, AA, et al. Good survival rates in systemic lupus erythematosus in south Sweden, while the mortality rate remains increased compared with the population. Lupus 2019;28:1488-94.
Lee YC, Choi SJ, Song GG. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus 2016;25:727-34.
Kedves M, Kósa F, Kunovszki P, et al. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. Rheumatology (Oxford) 2020;59:3443-51.
Bae EH, Lim SY, Han KD, et al. Systemic lupus erythematosus is a risk factor for cancer: a nationwide population-based study in Korea. Lupus 2019;28:317-323.
Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 2013;42:130-5.
Dreyer L, Faurschou M, Mogensen M, et al. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum 2011;63:3032-7.
Kaulen LD, Karschnia P, Dietrich J, et al. Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis. J Neurooncol 2020;149:153-9.
Seo MS, Yeo J, Hwang IC, et al. Risk of pancreatic cancer in patients with systemic lupus erythematosus: a meta-analysis. Clin Rheumatol 2019;38:3109-16.
Song L, Wang Y, Zhang J, et al. The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis. Arthritis Res Ther 2018;20:270.
Nayak P, Luo R, Elting L, et al. Impact of rheumatoid arthritis on the mortality of elderly patients who develop cancer: a population-based study. Arthritis Care Res (Hoboken) 2017;69:75-83.
Bultink IEM, de Vries F, van Vollenhoven RF, et al. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology (Oxford) 2021;60:207-216.
Mörth C, Valachis A, Abu Sabaa A, et al. Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome. Acta Oncol 2019;58:1170-7.
Fleck RM, McNeese MD, Ellerbroek NA, et al. Consequences of breast irradiation in patients with pre-existing collagen vascular diseases. Int J Radiat Oncol Biol Phys 1989;17:829-33.
Rakfal SD, Deutsch M. Radiotherapy for Malignancies associated with lupus: case reports of acute and late reactions. Am J Clin Oncol 1998;21:54-7.
Benk V, Al-Herz A, Gladman D, et al. Role of radiation therapy in patients with a diagnosis of both systemic lupus erythematosus and cancer. Arthritis Rheum 2005;53:67-72.
Chan K, Clark AE, Ramsey-Goldmann R, et al. Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment. Lupus 2018;27:120-3.
Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2002;16:847-58.
National Cancer Institute Surveillance: Epidemiology, and End Results Program. URL: https://seer.cancer.gov/.
Texas Health and Human Services: Texas Cancer Registry. URL: www.dshs.texas.gov/tcr.
Katz JN, Barrett J, Liang MH, et al. Sensitivity and positive predictive value of Medicare Part B physician claims for rheumatologic diagnoses and procedures. Arthritis Rheum 1997;40:1594-600.
Rector TS, Wickstrom SL, Shah M, et al. Specificity and sensitivity of claims-based algorithms for identifying members of Medicare+Choice health plans that have chronic medical conditions. Health Serv Res 2004;39:1839-57.
Cook MB, Drahos J, Wood S, et al. Pathogenesis and progression of oesophageal adenocarcinoma varies by prior diagnosis of Barrett's oesophagus. Br J Cancer 2016;115:1383-90.
Accordino MK, Wright JD, Buono D, et al. Incidence and predictors of diabetes mellitus after a diagnosis of early-stage breast cancer in the elderly using real-world data. Breast Cancer Res Treat 2020;183:201-11.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc 1999;94:496-509.
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258-67.
Garris C, Jhingran P, Bass D, et al. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan. J Med Econ 2013;16:667-77.
Speyer CB, Li D, Guan H, et al. Comparison of an administrative algorithm for SLE disease severity to clinical SLE Disease Activity Index scores. Rheumatol Int 2020;40:257-61.
Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233-41.